Efficacy and safety of CD24Fc in hospitalised patients with COVID-19: a randomised, double-blind, placebo-controlled, phase 3 study

BACKGROUND: Non-antiviral therapeutic options are required for the treatment of hospitalised patients with COVID-19. CD24Fc is an immunomodulator with potential to reduce the exaggerated inflammatory response to tissue injuries. We aimed to evaluate the safety and efficacy of CD24Fc in hospitalised...

Descripción completa

Detalles Bibliográficos
Autores principales: Welker, James, Pulido, Juan D, Catanzaro, Andrew T, Malvestutto, Carlos D, Li, Zihai, Cohen, Jonathan B, Whitman, Eric D, Byrne, Dana, Giddings, Olivia K, Lake, Jordan E, Chua, Joel V, Li, Ella, Chen, Jian, Zhou, Xiang, He, Kun, Gates, Davis, Kaur, Amarjot, Chen, Jamie, Chou, Hung-Yen, Devenport, Martin, Touomou, Raymond, Kottilil, Shyamasundaran, Liu, Yang, Zheng, Pan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8916779/
https://www.ncbi.nlm.nih.gov/pubmed/35286843
http://dx.doi.org/10.1016/S1473-3099(22)00058-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8916779/
https://www.ncbi.nlm.nih.gov/pubmed/35286843
http://dx.doi.org/10.1016/S1473-3099(22)00058-5

Ejemplares similares